Helen of Troy Limited (HELE) 10-Q 8 Jan 25 2025 Q3 Quarterly report Financial data

Cover page

Cover page - shares	9 Months Ended
	Nov. 30, 2024	Jan. 02, 2025
Entity Addresses [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Nov. 30, 2024
Document Transition Report	false
Entity File Number	001-14669
Entity Registrant Name	HELEN OF TROY LIMITED
Entity Incorporation, State or Country Code	D0
Entity Tax Identification Number	74-2692550
Entity Address, Address Line One	1 Helen of Troy Plaza
Entity Address, City or Town	El Paso
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	79912
City Area Code	915
Local Phone Number	225-8000
Title of 12(b) Security	Common Shares, $0.10 par value per share
Trading Symbol	HELE
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		22,855,739
Entity Central Index Key	0000916789
Current Fiscal Year End Date	--02-28
Document Fiscal Year Focus	2025
Document Fiscal Period Focus	Q3
Amendment Flag	false
Other Address
Entity Addresses [Line Items]
Entity Address, Address Line One	Clarendon House
Entity Address, Address Line Two	2 Church Street
Entity Address, City or Town	Hamilton
Entity Address, Country	BM

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Nov. 30, 2024	Feb. 29, 2024
Assets, current:
Cash and cash equivalents	$ 40,804	$ 18,501
Receivables, less allowances of $6,707 and $7,481	456,170	394,536
Inventory	450,740	395,995
Prepaid expenses and other current assets	36,215	27,012
Income taxes receivable	12,379	7,874
Total assets, current	996,308	843,918
Property and equipment, net of accumulated depreciation of $192,865 and $169,021	329,849	336,646
Goodwill	1,066,730	1,066,730
Other intangible assets, net of accumulated amortization of $200,488 and $186,882	524,105	536,696
Operating lease assets	36,031	35,962
Deferred tax assets, net	3,259	3,662
Other assets	16,849	15,008
Total assets	2,973,131	2,838,622
Liabilities, current:
Accounts payable	315,353	245,349
Accrued expenses and other current liabilities	182,759	181,391
Income taxes payable	11,066	17,821
Long-term debt, current maturities	8,594	6,250
Total liabilities, current	517,772	450,811
Long-term debt, excluding current maturities	725,297	659,421
Lease liabilities, non-current	40,867	37,262
Deferred tax liabilities, net	49,535	41,253
Other liabilities, non-current	11,484	12,433
Total liabilities	1,344,955	1,201,180
Commitments and contingencies
Stockholders' equity:
Cumulative preferred stock, non-voting, $1.00 par. Authorized 2,000,000 shares; none issued	0	0
Common stock, $0.10 par. Authorized 50,000,000 shares; 22,853,038 and 23,751,258 shares issued and outstanding	2,285	2,375
Additional paid in capital	361,796	348,739
Accumulated other comprehensive income	3,243	2,099
Retained earnings	1,260,852	1,284,229
Total stockholders' equity	1,628,176	1,637,442
Total liabilities and stockholders' equity	$ 2,973,131	$ 2,838,622

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Nov. 30, 2024	Feb. 29, 2024
Statement of Financial Position [Abstract]
Allowance on receivables	$ 6,707	$ 7,481
Property and equipment, accumulated depreciation	192,865	169,021
Other intangible assets, accumulated amortization	$ 200,488	$ 186,882
Cumulative preferred stock, nonvoting, par value (in dollars per share)	$ 1	$ 1
Cumulative preferred stock, non-voting, authorized shares (in shares)	2,000,000	2,000,000
Cumulative preferred stock, non-voting, issued shares (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.10	$ 0.10
Common stock, authorized shares (in shares)	50,000,000	50,000,000
Common stock, shares issued (in shares)	22,853,038	23,751,258
Common stock, shares outstanding (in shares)	22,853,038	23,751,258

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Nov. 30, 2024	Nov. 30, 2023	Nov. 30, 2024	Nov. 30, 2023
Income Statement [Abstract]
Sales revenue, net	$ 530,706	$ 549,614	$ 1,421,774	$ 1,515,849
Cost of goods sold	271,378	285,833	743,297	806,784
Gross profit	259,328	263,781	678,477	709,065
Selling, general and administrative expense (“SG&A”)	180,692	152,964	530,865	499,790
Restructuring charges	3,518	3,890	6,879	14,862
Operating income	75,118	106,927	140,733	194,413
Non-operating income, net	198	180	468	465
Interest expense	12,164	12,859	37,923	40,565
Income before income tax	63,152	94,248	103,278	154,313
Income tax expense	13,536	18,350	30,444	28,453
Net income	$ 49,616	$ 75,898	$ 72,834	$ 125,860
Earnings per share (“EPS”):
Basic (in dollars per share)	$ 2.17	$ 3.20	$ 3.16	$ 5.27
Diluted (in dollars per share)	$ 2.17	$ 3.19	$ 3.15	$ 5.25
Weighted average shares used in computing EPS:
Basic (in shares)	22,853	23,743	23,064	23,903
Diluted (in shares)	22,882	23,813	23,118	23,996

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Nov. 30, 2024	Nov. 30, 2023	Nov. 30, 2024	Nov. 30, 2023
Statement of Comprehensive Income [Abstract]
Net income	$ 49,616	$ 75,898	$ 72,834	$ 125,860
Other comprehensive income (loss), net of tax:
Cash flow hedge activity - interest rate swaps	1,934	(1,686)	(587)	(2,010)
Cash flow hedge activity - foreign currency contracts	2,824	58	1,731	(879)
Total other comprehensive income (loss), net of tax	4,758	(1,628)	1,144	(2,889)
Comprehensive income	$ 54,374	$ 74,270	$ 73,978	$ 122,971

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid in Capital	Accumulated Other Comprehensive Income (Loss)	Retained Earnings
Beginning balance (in shares) at Feb. 28, 2023		23,994
Beginning balance at Feb. 28, 2023	$ 1,488,811	$ 2,399	$ 317,277	$ 4,947	$ 1,164,188
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	22,581				22,581
Other comprehensive income (loss), net of tax	(3,715)			(3,715)
Exercise of stock options (in shares)		5
Exercise of stock options	212	$ 1	211
Issuance and settlement of restricted stock (in shares)		120
Issuance and settlement of restricted stock	0	$ 12	(12)
Issuance of common stock related to stock purchase plan (in shares)		23
Issuance of common stock related to stock purchase plan	2,168	$ 2	2,166
Common stock repurchased and retired (in shares)		(45)
Common stock repurchased and retired	(4,446)	$ (4)	(4,442)
Share-based compensation	9,297		9,297
Ending balance (in shares) at May. 31, 2023		24,097
Ending balance at May. 31, 2023	1,514,908	$ 2,410	324,497	1,232	1,186,769
Beginning balance (in shares) at Feb. 28, 2023		23,994
Beginning balance at Feb. 28, 2023	1,488,811	$ 2,399	317,277	4,947	1,164,188
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Other comprehensive income (loss), net of tax	(2,889)
Ending balance (in shares) at Nov. 30, 2023		23,744
Ending balance at Nov. 30, 2023	1,586,278	$ 2,374	340,351	2,058	1,241,495
Beginning balance (in shares) at May. 31, 2023		24,097
Beginning balance at May. 31, 2023	1,514,908	$ 2,410	324,497	1,232	1,186,769
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	27,381				27,381
Other comprehensive income (loss), net of tax	2,454			2,454
Issuance and settlement of restricted stock (in shares)		4
Common stock repurchased and retired (in shares)		(382)
Common stock repurchased and retired	(50,089)	$ (38)	(1,499)		(48,552)
Share-based compensation	7,229		7,229
Ending balance (in shares) at Aug. 31, 2023		23,719
Ending balance at Aug. 31, 2023	1,501,883	$ 2,372	330,227	3,686	1,165,598
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	75,898				75,898
Other comprehensive income (loss), net of tax	(1,628)			(1,628)
Exercise of stock options (in shares)		1
Exercise of stock options	53		53
Issuance and settlement of restricted stock (in shares)		8
Issuance and settlement of restricted stock	0	$ 1	(1)
Issuance of common stock related to stock purchase plan (in shares)		19
Issuance of common stock related to stock purchase plan	1,799	$ 2	1,797
Common stock repurchased and retired (in shares)		(3)
Common stock repurchased and retired	(306)	$ (1)	(304)		(1)
Share-based compensation	8,579		8,579
Ending balance (in shares) at Nov. 30, 2023		23,744
Ending balance at Nov. 30, 2023	1,586,278	$ 2,374	340,351	2,058	1,241,495
Beginning balance (in shares) at Feb. 29, 2024		23,751
Beginning balance at Feb. 29, 2024	1,637,442	$ 2,375	348,739	2,099	1,284,229
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	6,204				6,204
Other comprehensive income (loss), net of tax	698			698
Exercise of stock options (in shares)		6
Exercise of stock options	352	$ 1	351
Issuance and settlement of restricted stock (in shares)		71
Issuance and settlement of restricted stock	0	$ 7	(7)
Issuance of common stock related to stock purchase plan (in shares)		19
Issuance of common stock related to stock purchase plan	2,006	$ 2	2,004
Common stock repurchased and retired (in shares)		(1,037)
Common stock repurchased and retired	(103,035)	$ (104)	(6,720)		(96,211)
Share-based compensation	5,833		5,833
Ending balance (in shares) at May. 31, 2024		22,810
Ending balance at May. 31, 2024	1,549,500	$ 2,281	350,200	2,797	1,194,222
Beginning balance (in shares) at Feb. 29, 2024		23,751
Beginning balance at Feb. 29, 2024	1,637,442	$ 2,375	348,739	2,099	1,284,229
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Other comprehensive income (loss), net of tax	1,144
Ending balance (in shares) at Nov. 30, 2024		22,853
Ending balance at Nov. 30, 2024	1,628,176	$ 2,285	361,796	3,243	1,260,852
Beginning balance (in shares) at May. 31, 2024		22,810
Beginning balance at May. 31, 2024	1,549,500	$ 2,281	350,200	2,797	1,194,222
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	17,014				17,014
Other comprehensive income (loss), net of tax	(4,312)			(4,312)
Issuance and settlement of restricted stock (in shares)		6
Common stock repurchased and retired (in shares)		(1)
Common stock repurchased and retired	(109)		(109)
Share-based compensation	5,487		5,487
Ending balance (in shares) at Aug. 31, 2024		22,815
Ending balance at Aug. 31, 2024	1,567,580	$ 2,281	355,578	(1,515)	1,211,236
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	49,616				49,616
Other comprehensive income (loss), net of tax	4,758			4,758
Issuance and settlement of restricted stock (in shares)		5
Issuance and settlement of restricted stock	0	$ 1	(1)
Issuance of common stock related to stock purchase plan (in shares)		33
Issuance of common stock related to stock purchase plan	1,522	$ 3	1,519
Common stock repurchased and retired	(30)		(30)
Share-based compensation	4,730		4,730
Ending balance (in shares) at Nov. 30, 2024		22,853
Ending balance at Nov. 30, 2024	$ 1,628,176	$ 2,285	$ 361,796	$ 3,243	$ 1,260,852

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Nov. 30, 2024	Nov. 30, 2023
Cash provided by operating activities:
Net income	$ 72,834	$ 125,860
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	40,850	37,037
Amortization of financing costs	957	923
Non-cash operating lease expense	8,583	7,537
Provision for credit losses	(537)	5,421
Non-cash share-based compensation	16,050	25,105
Gain on sale of distribution and office facilities	0	(34,190)
Gain on the sale or disposal of property and equipment	(10)	(326)
Deferred income taxes and tax credits	8,400	13,430
Changes in operating capital:
Receivables	(61,806)	(87,575)
Inventory	(54,745)	29,459
Prepaid expenses and other current assets	(9,700)	(5,507)
Other assets and liabilities, net	(428)	(1,082)
Accounts payable	71,042	102,295
Accrued expenses and other current liabilities	(2,845)	22,484
Accrued income taxes	(10,409)	(8,412)
Net cash provided by operating activities	78,236	232,459
Cash (used) provided by investing activities:
Capital and intangible asset expenditures	(22,155)	(29,681)
Payments for purchases of U.S. Treasury Bills	(3,441)	(7,373)
Proceeds from the maturity of U.S. Treasury Bills	1,872	0
Proceeds from sale of distribution and office facilities	0	49,456
Proceeds from the sale of property and equipment	145	1,609
Net cash (used) provided by investing activities	(23,579)	14,011
Cash used by financing activities:
Proceeds from revolving loans	747,840	635,800
Repayment of revolving loans	(675,890)	(830,800)
Repayment of long-term debt	(4,687)	(4,687)
Payment of financing costs	(323)	0
Proceeds from share issuances under share-based compensation plans	3,880	4,232
Payments for repurchases of common stock	(103,174)	(54,841)
Net cash used by financing activities	(32,354)	(250,296)
Net increase (decrease) in cash and cash equivalents	22,303	(3,826)
Cash and cash equivalents, beginning balance	18,501	29,073
Cash and cash equivalents, ending balance	40,804	25,247
Supplemental non-cash investing activity:
Capital expenditures included in accounts payable and accrued expenses	$ 6,935	$ 2,439

Basis of Presentation and Relat

Basis of Presentation and Related Information	9 Months Ended
	Nov. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Related Information	Note 1 - Basis of Presentation and Related Information Corporate Overview The accompanying condensed consolidated financial statements contain all adjustments (consisting of normal recurring adjustments) necessary to present fairly our consolidated financial position as of November 30, 2024 and February 29, 2024, and the results of our consolidated operations for the interim periods presented. We follow the same accounting policies when preparing quarterly financial data as we use for preparing annual data. These statements should be read in conjunction with the consolidated financial statements and the notes included in our latest annual report on Form 10-K for the fiscal year ended February 29, 2024 (“Form 10-K”), and our other reports on file with the Securities and Exchange Commission (the “SEC”). When used in these notes, unless otherwise indicated or the context suggests otherwise, references to “the Company”, “our Company”, “Helen of Troy”, “we”, “us”, or “our” refer to Helen of Troy Limited and its subsidiaries, which are all wholly-owned. We refer to our common shares, par value $0.10 per share, as “common stock.” References to “fiscal” in connection with a numeric year number denotes our fiscal year ending on the last day of February, during the year number listed. References to “the FASB” refer to the Financial Accounting Standards Board. References to “GAAP” refer to accounting principles generally accepted in the United States of America (the “U.S.”). References to “ASU” refer to the codification of GAAP in the Accounting Standards Updates issued by the FASB. References to “ASC” refer to the codification of GAAP in the Accounting Standards Codification issued by the FASB. We incorporated as Helen of Troy Corporation in Texas in 1968 and were reorganized as Helen of Troy Limited in Bermuda in 1994. We are a leading global consumer products company offering creative products and solutions for our customers through a diversified portfolio of brands. Our portfolio of brands includes OXO, Hydro Flask, Osprey, Vicks, Braun, Honeywell, PUR, Hot Tools, Drybar, Curlsmith and Revlon, among others. As of November 30, 2024, we operated two reportable segments: Home & Outdoor and Beauty & Wellness. Our Home & Outdoor segment offers a broad range of outstanding world-class brands that help consumers enjoy everyday living inside their homes and outdoors. Our innovative products for home activities include food preparation and storage, cooking, cleaning, organization, and beverage service. Our outdoor performance range, on-the-go food storage, and beverageware includes lifestyle hydration products, coolers and food storage solutions, backpacks, and travel gear. The Beauty & Wellness segment provides consumers with a broad range of outstanding world-class brands for beauty and wellness. In Beauty, we deliver innovation through products such as hair styling appliances, grooming tools, and liquid and aerosol personal care products that help consumers look and feel more beautiful. In Wellness, we are there when you need us most with highly regarded humidifiers, thermometers, water and air purifiers, heaters, and fans. Our business is seasonal due to different calendar events, holidays and seasonal weather and illness patterns. Our fiscal reporting period ends on the last day in February. Historically, our highest sales volume and operating income occur in our third fiscal quarter ending November 30th. We purchase our products from unaffiliated manufacturers, most of which are located in China, Mexico, Vietnam and the U.S. During fiscal 2023, we initiated a global restructuring plan intended to expand operating margins through initiatives designed to improve efficiency and effectiveness and reduce costs (referred to as “Project Pegasus”). See Note 6 for additional information. On September 28, 2023, we completed the sale of our distribution and office facilities in El Paso, Texas for a sales price of $50.6 million, less transaction costs of $1.1 million. Concurrently, we entered into an agreement to leaseback the office facilities for a period of up to 18 months substantially rent free, which we estimated to have a fair value of approximately $1.9 million. The transaction qualified for sales recognition under the sale leaseback accounting requirements. Accordingly, we increased the sales price by the $1.9 million of prepaid rent and recognized a gain on the sale of $34.2 million within SG&A during the third quarter of fiscal year 2024, of which $18.0 million and $16.2 million was recognized by our Beauty & Wellness and Home & Outdoor segments, respectively. The related property and equipment totaling $17.2 million, net of accumulated depreciation of $36.8 million, was derecognized from the consolidated balance sheet, and at lease commencement, we recorded an operating lease asset, which includes the imputed rent payments described above, and an operating lease liability. We used the proceeds from the sale to repay amounts outstanding under our long-term debt agreement. Principles of Consolidation The accompanying condensed consolidated financial statements are prepared in accordance with GAAP and include all of our subsidiaries. Our condensed consolidated financial statements are prepared in U.S. Dollars. All intercompany balances and transactions are eliminated in consolidation. The preparation of consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. Actual results may differ materially from those estimates. During the second quarter of fiscal 2025, we concluded that a goodwill impairment triggering event had occurred primarily due to a sustained decline in our stock price. Additional factors that contributed to this conclusion included current macroeconomic trends and uncertainty surrounding inflation and high interest rates, which negatively impact consumer disposable income, credit availability, spending and overall consumer confidence, all of which had and may continue to adversely impact our sales, results of operations and cash flows. These factors were applicable to all of our reporting units which resulted in us performing quantitative goodwill impairment testing on all of our reporting units. We considered whether these events and circumstances would affect any other assets and concluded we should perform quantitative impairment testing on our indefinite-lived trademark licenses and trade names and our definite-lived trademark licenses, trade names, and customer lists. We performed quantitative impairment testing on our goodwill and intangible assets described above and determined none were impaired. Accordingly during the second quarter of fiscal 2025, no impairment charges were recorded. During the third quarter of fiscal 2025, we determined no changes in circumstances or conditions or events have occurred that would indicate the carrying value of our goodwill and intangible assets may not be recoverable. For additional information, refer to “Critical Accounting Policies and Estimates” in Item 2., “Management's Discussion and Analysis of Financial Condition and Results of Operations”.

New Accounting Pronouncements

New Accounting Pronouncements	9 Months Ended
	Nov. 30, 2024
Accounting Changes and Error Corrections [Abstract]
New Accounting Pronouncements	Note 2 - New Accounting Pronouncements Except for the changes discussed below, there have been no changes in the information provided in our Form 10-K. Not Yet Adopted In November 2024, the FASB issued ASU 2024-03, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	9 Months Ended
	Nov. 30, 2024
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	Note 3 - Accrued Expenses and Other Current Liabilities A summary of accrued expenses and other current liabilities was as follows: (in thousands) November 30, 2024 February 29, 2024 Accrued compensation, benefits and payroll taxes $ 19,125 $ 36,572 Accrued sales discounts and allowances 48,839 37,851 Accrued sales returns 22,118 21,282 Accrued advertising 34,658 29,212 Other 58,019 56,474 Total accrued expenses and other current liabilities $ 182,759 $ 181,391

Share-Based Compensation Plans

Share-Based Compensation Plans	9 Months Ended
	Nov. 30, 2024
Share-Based Payment Arrangement [Abstract]
Share-Based Compensation Plans	Note 4 - Share-Based Compensation Plans As part of our compensation structure, we grant share-based compensation awards to certain employees and non-employee members of our Board of Directors during the fiscal year. These awards may be subject to attainment of certain service conditions, performance conditions and/or market conditions. During the first quarter of fiscal 2025, we granted 94,900 service condition awards (“Service Condition Awards”) with a weighted average grant date fair value of $124.37. Additionally, we granted 157,797 performance-based awards during the first quarter of fiscal 2025, of which 94,586 contained performance conditions (“Performance Condition Awards”) and 63,211 contained market conditions (“Market Condition Awards”), with weighted average grant date fair values of $124.37 and $91.19, respectively. Refer to our Form 10-K for further information on the Company's share-based compensation plans. We recorded share-based compensation expense in SG&A as follows: Three Months Ended November 30, Nine Months Ended (in thousands) 2024 2023 2024 2023 Directors stock compensation $ 197 $ 197 $ 589 $ 590 Service Condition Awards 2,711 3,160 8,105 9,358 Performance Condition Awards 563 1,170 2,703 4,306 Market Condition Awards 842 3,458 3,609 9,647 Employee stock purchase plan 417 594 1,044 1,204 Share-based compensation expense 4,730 8,579 16,050 25,105 Less: income tax benefits (354) (532) (839) (1,558) Share-based compensation expense, net of income tax benefits $ 4,376 $ 8,047 $ 15,211 $ 23,547 Unrecognized Share-Based Compensation Expense As of November 30, 2024, our total unrecognized share-based compensation for all awards was $22.5 million, which will be recognized over a weighted average amortization period of 2.1 years. The total unrecognized share-based compensation reflects an estimate of target achievement for Performance Condition Awards granted during fiscal 2025 and fiscal 2024 and an estimate of zero percent of target achievement for Performance Condition Awards granted during fiscal 2023.

Repurchases of Common Stock

Repurchases of Common Stock	9 Months Ended
	Nov. 30, 2024
Equity [Abstract]
Repurchases of Common Stock	Note 5 - Repurchases of Common Stock In August 2024, our Board of Directors authorized the repurchase of up to $500 million of our outstanding common stock. The authorization became effective August 20, 2024, for a period of three years, and replaced our former repurchase authorization, of which approximately $245.3 million remained. As of November 30, 2024, our repurchase authorization allowed for the purchase of $499.9 million of common stock. Our current equity-based compensation plans include provisions that allow for the “net exercise” of share-settled awards by all plan participants. In a net exercise, any required payroll taxes, federal withholding taxes and exercise price of the shares due from the option or other share-based award holders are settled by having the holder tender back to us a number of shares at fair value equal to the amounts due. Net exercises are treated as purchases and retirements of shares. The following table summarizes our share repurchase activity for the periods shown: Three Months Ended November 30, Nine Months Ended November 30, (in thousands, except share and per share data) 2024 2023 2024 2023 Common stock repurchased on the open market: Number of shares — — 1,011,243 381,200 Aggregate value of shares $ — $ — $ 100,019 $ 50,006 Average price per share $ — $ — $ 98.91 $ 131.18 Common stock received in connection with share-based compensation: Number of shares 448 2,701 27,223 48,098 Aggregate value of shares $ 30 $ 306 $ 3,155 $ 4,835 Average price per share $ 66.34 $ 113.31 $ 115.89 $ 100.51

Restructuring Plan

Restructuring Plan	9 Months Ended
	Nov. 30, 2024
Restructuring and Related Activities [Abstract]
Restructuring Plan	Note 6 - Restructuring Plan During fiscal 2023, we initiated Project Pegasus, a global restructuring plan intended to expand operating margins through initiatives designed to improve efficiency and effectiveness and reduce costs. Project Pegasus includes initiatives to further optimize our brand portfolio, streamline and simplify the organization, accelerate and amplify cost of goods savings projects, enhance the efficiency of our supply chain network, optimize our indirect spending and improve our cash flow and working capital, as well as other activities. We anticipate these initiatives will create operating efficiencies, as well as provide a platform to fund future growth investments. During the fourth quarter of fiscal 2023, we made changes to the structure of our organization. These changes resulted in our previous Health & Wellness and Beauty operating segments being combined into a single reportable segment, the creation of a North America Regional Market Organization (“RMO”) responsible for sales and go-to-market strategies for all categories and channels in the U.S. and Canada, and further centralization of certain functions under shared services, particularly in operations and finance to better support our business segments and RMOs. This new structure reduced the size of our global workforce by approximately 10%. We believe that these changes better focus business segment resources on brand development, consumer-centric innovation and marketing, the RMOs on sales and go to market strategies, and shared services on their respective areas of expertise while also creating a more efficient and effective organizational structure. During the second quarter of fiscal 2024, we announced plans to geographically consolidate the U.S. Beauty business, located in El Paso, Texas, and Irvine, California, and co-locate it with our Wellness business in the Boston, Massachusetts area. This geographic consolidation and relocation aligns with our initiative to streamline and simplify the organization and was completed during the third quarter of fiscal 2025. We expect these changes to enable a greater opportunity to capture synergies and enhance collaboration and innovation within the Beauty & Wellness segment. As previously disclosed, we continue to have the following expectations regarding Project Pegasus charges: • Total one-time pre-tax restructuring charges of approximately $50 million to $55 million over the duration of the plan, expected to be completed during fiscal 2025. • Pre-tax restructuring charges to be comprised of approximately $15 million to $19 million of severance and employee related costs, $28 million of professional fees, $3 million to $4 million of contract termination costs, and $4 million of other exit and disposal costs. • All of our operating segments and shared services will be impacted by the plan and pre-tax restructuring charges include approximately $16 million to $17 million in Home & Outdoor and $34 million to $38 million in Beauty & Wellness. • Pre-tax restructuring charges represent primarily cash expenditures, which are expected to be substantially paid by the end of fiscal 2025. We also continue to have the following expectations regarding Project Pegasus savings: • Targeted annualized pre-tax operating profit improvements of approximately $75 million to $85 million, which began in fiscal 2024 and we expect to be substantially achieved by the end of fiscal 2027. • Estimated cadence of the recognition of the savings will be approximately 25% in fiscal 2024, which was achieved, approximately 35% in fiscal 2025, approximately 25% in fiscal 2026 and approximately 15% in fiscal 2027. • Total profit improvements to be realized approximately 60% through reduced cost of goods sold and 40% through lower SG&A. During the three and nine month periods ended November 30, 2024, we incurred $3.5 million and $6.9 million, respectively, of pre-tax restructuring costs in connection with Project Pegasus, which were recorded as “Restructuring charges” in the condensed consolidated statements of income. We recognized $3.9 million and $14.9 million of pre-tax restructuring costs during the three and nine month periods ended November 30, 2023, respectively, in connection with Project Pegasus. The following tables summarize restructuring charges recorded as a result of Project Pegasus for the periods presented: Three Months Ended November 30, 2024 (in thousands) Home & Beauty & Total Severance and employee related costs $ 130 $ 489 $ 619 Professional fees 59 355 414 Contract termination — 1,747 1,747 Other 581 157 738 Total restructuring charges $ 770 $ 2,748 $ 3,518 Three Months Ended November 30, 2023 (in thousands) Home & Beauty & Total Severance and employee related costs $ 109 $ 2,498 $ 2,607 Professional fees 464 794 1,258 Contract termination — — — Other 10 15 25 Total restructuring charges $ 583 $ 3,307 $ 3,890 Nine Months Ended November 30, 2024 Total (in thousands) Home & Beauty & Wellness Total Severance and employee related costs $ 820 $ 2,155 $ 2,975 $ 18,251 Professional fees 327 940 1,267 28,144 Contract termination — 1,747 1,747 3,078 Other 581 309 890 3,480 Total restructuring charges $ 1,728 $ 5,151 $ 6,879 $ 52,953 Nine Months Ended November 30, 2023 (in thousands) Home & Beauty & Total Severance and employee related costs $ 680 $ 3,407 $ 4,087 Professional fees 3,915 5,870 9,785 Contract termination — 796 796 Other 49 145 194 Total restructuring charges $ 4,644 $ 10,218 $ 14,862 The tables below present a rollforward of our accruals related to Project Pegasus, which are included in accounts payable and accrued expenses and other current liabilities: (in thousands) Balance at February 29, 2024 Charges Payments Balance at November 30, 2024 Severance and employee related costs $ 4,493 $ 2,975 $ (5,885) $ 1,583 Professional fees 272 1,267 (1,303) 236 Contract termination — 1,747 (1,735) 12 Other — 890 (890) — Total $ 4,765 $ 6,879 $ (9,813) $ 1,831 (in thousands) Balance at February 28, 2023 Charges Payments Balance at November 30, 2023 Severance and employee related costs $ 3,173 $ 4,087 $ (3,758) $ 3,502 Professional fees 3,201 9,785 (12,559) 427 Contract termination 160 796 (956) — Other 34 194 (228) — Total $ 6,568 $ 14,862 $ (17,501) $ 3,929

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Nov. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 7 - Commitments and Contingencies Legal Matters We are involved in various legal claims and proceedings in the normal course of operations. We believe the outcome of these matters will not have a material adverse effect on our consolidated financial position, results of operations or liquidity, except as described below. On December 23, 2021, Brita LP filed a complaint against Kaz USA, Inc. and Helen of Troy Limited in the United States District Court for the Western District of Texas (the “Patent Litigation”), alleging patent infringement by the Company relating to its PUR gravity-fed water filtration systems. In the Patent Litigation, Brita LP seeks monetary damages and injunctive relief relating to the alleged infringement. Brita LP simultaneously filed a complaint with the United States International Trade Commission (“ITC”) against Kaz USA, Inc., Helen of Troy Limited and five other unrelated companies that sell water filtration systems (the “ITC Action”). The complaint in the ITC Action also alleged patent infringement by the Company with respect to a limited set of PUR gravity-fed water filtration systems. In the ITC Action, Brita LP requested the ITC to initiate an unfair import investigation relating to such filtration systems. This action sought injunctive relief to prevent entry of certain accused PUR products (and certain other products) into the U.S. and cessation of marketing and sales of existing inventory that is already in the U.S. On January 25, 2022, the ITC instituted the investigation requested by the ITC Action. Discovery closed in the ITC Action in May 2022, and approximately half of the originally identified PUR gravity-fed water filters were removed from the case and are no longer included in the ITC Action. In August 2022, the parties participated in the evidentiary hearing, with additional supplemental hearings in October 2022. On February 28, 2023, the ITC issued an Initial Determination in the ITC Action, tentatively ruling against the Company and the other unrelated respondents. The ITC has a guaranteed review process, and thus all respondents, including the Company, filed a petition with the ITC for a full review of the Initial Determination. On September 19, 2023, the ITC issued its Final Determination in the Company’s favor. The ITC determined there was no violation by the Company and terminated the investigation. Brita LP is appealing the ITC's decision to the Federal Circuit (“CAFC Appeal”) and filed its Notice of Appeal on October 24, 2023. The Company intervened in the CAFC Appeal, but as of the filing date of this Form 10-Q, no hearings have been scheduled. The Patent Litigation remains stayed for the time being. We cannot predict the outcome of these legal proceedings, the amount or range of any potential loss, when the proceedings will be resolved, or customer acceptance of any replacement water filter. Litigation is inherently unpredictable, and the resolution or disposition of these proceedings could, if adversely determined, have a material and adverse impact on our financial position and results of operations. Regulatory Matters During fiscal 2022 and 2023, we were in discussions with the U.S. Environmental Protection Agency (the “EPA”) regarding the compliance of packaging claims on certain of our products in the air and water filtration categories and a limited subset of humidifier products within the Beauty & Wellness segment that are sold in the U.S. The EPA did not raise any product quality, safety or performance issues. As a result of these packaging compliance discussions, we voluntarily implemented a temporary stop shipment action on the impacted products as we worked with the EPA towards an expedient resolution. We resumed normalized levels of shipping of the affected inventory during fiscal 2022 and we completed the repackaging and relabeling of our existing inventory of impacted products during fiscal 2023. Additionally, as a result of continuing dialogue with the EPA, we executed further repackaging and relabeling plans on certain additional humidifier products and certain additional air filtration products, which were also completed during fiscal 2023. Ongoing settlement discussions with the EPA related to this matter may result in the imposition of fines or penalties in the future. Such potential fines or penalties cannot be reasonably estimated. For additional information refer to Part I, Item 2., “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” including “EPA Compliance Costs”.

Long-Term Debt

Long-Term Debt	9 Months Ended
	Nov. 30, 2024
Debt Disclosure [Abstract]
Long-Term Debt	Note 8 - Long-Term Debt A summary of our long-term debt follows: (in thousands) November 30, 2024 February 29, 2024 Credit Agreement (1): Revolving loans $ 493,900 $ 421,950 Term loans 245,313 250,000 Total borrowings under Credit Agreement 739,213 671,950 Unamortized prepaid financing fees (5,322) (6,279) Total long-term debt 733,891 665,671 Less: current maturities of long-term debt (8,594) (6,250) Long-term debt, excluding current maturities $ 725,297 $ 659,421 (1) The weighted average interest rates on borrowings outstanding under the Credit Agreement (defined below) inclusive of the impact of our interest rate swaps as of November 30, 2024 and February 29, 2024 were 5.5% and 6.0%, respectively. Capitalized Interest During the three month periods ended November 30, 2024 and November 30, 2023, we incurred interest costs totaling $12.2 million and $12.9 million, respectively, of which none was capitalized. During the nine month period ended November 30, 2024, we incurred interest costs totaling $37.9 million, of which none was capitalized, compared to $41.5 million for the same period last year, of which we capitalized $0.9 million as part of property and equipment in connection with the construction of a new distribution facility. Credit Agreement We have a credit agreement (the “Credit Agreement”) with Bank of America, N.A., as administrative agent, and other lenders that provides for aggregate commitments of $1.5 billion, which are available through (i) a $1.0 billion revolving credit facility, which includes a $50 million sublimit for the issuance of letters of credit, (ii) a $250 million term loan facility, and (iii) a committed $250 million delayed draw term loan facility, which may be borrowed in multiple drawdowns until August 15, 2025. Proceeds can be used for working capital and other general corporate purposes, including funding permitted acquisitions. At the closing date, February 15, 2024, we borrowed $457.5 million under the revolving credit facility and $250.0 million under the term loan facility and utilized the proceeds to repay all debt outstanding under our prior credit agreement. The Credit Agreement matures on February 15, 2029. The Credit Agreement includes an accordion feature, which permits the Company to request to increase its borrowing capacity by an additional $300 million plus an unlimited amount when the Leverage Ratio (as defined in the Credit Agreement) on a pro-forma basis is less than 3.25 to 1.00. The term loans are payable at the end of each fiscal quarter in equal installments of 0.625% through February 28, 2025, 0.9375% through February 28, 2026, and 1.25% thereafter of the original principal balance of the term loans, which began in the first quarter of fiscal 2025, with the remaining balance due at the maturity date. Borrowings under the Credit Agreement bear floating interest at either the Base Rate or Term SOFR (as defined in the Credit Agreement), plus a margin based on the Net Leverage Ratio (as defined in the Credit Agreement) of 0% to 1.125% and 1.0% to 2.125% for Base Rate and Term SOFR borrowings, respectively. The floating interest rates on our borrowings under the Credit Agreement are hedged with interest rate swaps to effectively fix interest rates on $550 million and $500 million of the outstanding principal balance under the Credit Agreement as of November 30, 2024 and February 29, 2024, respectively. See Notes 9, 10, and 11 for additional information regarding our interest rate swaps. As of November 30, 2024, the balance of outstanding letters of credit was $9.5 million and the amount available for revolving loans under the Credit Agreement was $496.6 million. Covenants in the Credit Agreement limit the amount of total indebtedness we can incur. As of November 30, 2024, these covenants effectively limited our ability to incur more than $298.8 million of additional debt from all sources, including the Credit Agreement, or $496.6 million in the event a qualified acquisition is consummated. Debt Covenants As of November 30, 2024, we were in compliance with all covenants as defined under the terms of the Credit Agreement.

Fair Value

Fair Value	9 Months Ended
	Nov. 30, 2024
Fair Value Disclosures [Abstract]
Fair Value	Note 9 - Fair Value Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Valuation techniques under the accounting guidance related to fair value measurements are based on observable and unobservable inputs. These inputs are classified into the following hierarchy: Level 1: Quoted prices for identical assets or liabilities in active markets; Level 2: Observable inputs other than quoted prices that are directly or indirectly observable for the asset or liability, including quoted prices for similar assets or liabilities in active markets; quoted prices for similar or identical assets or liabilities in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable; and Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions. All of our financial assets and liabilities, except for our investments in U.S. Treasury Bills, are classified as Level 2 because their valuation is dependent on observable inputs and other quoted prices for similar assets or liabilities, or model-derived valuations whose significant value drivers are observable. Our investments in U.S. Treasury Bills are classified as Level 1 because their value is based on quoted prices in active markets for identical assets. The following table presents the fair value of our financial assets and liabilities: Fair Value (in thousands) November 30, 2024 February 29, 2024 Assets: Cash equivalents (money market accounts) $ 8,898 $ 462 U.S. Treasury Bills 10,715 8,948 Interest rate swaps 1,738 2,504 Foreign currency derivatives 2,496 592 Total assets $ 23,847 $ 12,506 Liabilities: Interest rate swaps $ — $ — Foreign currency derivatives 95 386 Total liabilities $ 95 $ 386 All of our financial assets and liabilities, except for our investments in U.S. Treasury Bills, are measured and recorded at fair value on a recurring basis. Our investments in U.S. Treasury Bills are recorded at amortized cost. As of both November 30, 2024 and February 29, 2024, the current carrying amounts of our U.S. Treasury Bills were $2.5 million and were included within Prepaid expenses and other current assets in our condensed consolidated balance sheets. As of November 30, 2024 and February 29, 2024, the non-current carrying amounts of our U.S. Treasury Bills were $8.2 million and $6.6 million, respectively, and were included within Other assets in our condensed consolidated balance sheets. The carrying amounts of cash, accounts payable, accrued expenses and other current liabilities and income taxes payable approximate fair value because of the short maturity of these items. The carrying amounts of receivables approximate fair value due to the effect of the related allowance for credit losses. The carrying amount of our floating rate long-term debt approximates its fair value. Our investments in U.S. Treasury Bills are classified as held-to-maturity because we have the positive intent and ability to hold the securities to maturity. We invest in U.S. Treasury Bills with maturities ranging from less than one We use foreign currency forward contracts and interest rate swaps to manage our exposure to changes in foreign currency exchange rates and interest rates, respectively. All of our derivative assets and liabilities are recorded at fair value. See Notes 10 and 11 for more information on our derivatives.

Financial Instruments and Risk

Financial Instruments and Risk Management	9 Months Ended
	Nov. 30, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Financial Instruments and Risk Management	Note 10 - Financial Instruments and Risk Management Foreign Currency Risk The U.S. Dollar is the functional currency for the Company and all of its subsidiaries and is also the reporting currency for the Company. By operating internationally, we are subject to foreign currency risk from transactions denominated in currencies other than the U.S. Dollar (“foreign currencies”). Such transactions include sales and operating expenses. As a result of such transactions, portions of our cash, accounts receivable and accounts payable are denominated in foreign currencies. Approximately 14% of our net sales revenue was denominated in foreign currencies during both the three and nine month periods ended November 30, 2024 and both the three and nine month periods ended November 30, 2023. These sales were primarily denominated in Euros, British Pounds and Canadian Dollars. We make most of our inventory purchases from manufacturers in Asia and primarily use the U.S. Dollar for such purchases. In our condensed consolidated statements of income, foreign currency exchange rate gains and losses resulting from the remeasurement of foreign income tax receivables and payables, and deferred income tax assets and liabilities are recognized in income tax expense, and all other foreign currency exchange rate gains and losses are recognized in SG&A. During the three and nine month periods ended November 30, 2024, we recorded foreign currency exchange rate net losses of $0.5 million and $0.8 million, respectively, in income tax expense, compared to net gains of $0.1 million and $0.5 million for the same periods last year, respectively. During the three and nine month periods ended November 30, 2024, we recorded foreign currency exchange rate net losses of $1.4 million and $0.8 million, respectively, in SG&A, compared to net gains of $0.1 million and net losses of $0.3 million for the same periods last year, respectively. We mitigate certain foreign currency exchange rate risk by using forward contracts to protect against the foreign currency exchange rate risk inherent in our transactions denominated in foreign currencies. We do not enter into any derivatives or similar instruments for trading or other speculative purposes. Certain of our forward contracts are designated as cash flow hedges (“foreign currency contracts”) and are recorded on the balance sheet at fair value with changes in fair value recorded in Other Comprehensive Income (Loss) (“OCI”) until the hedge transaction is settled, at which point amounts are reclassified from Accumulated Other Comprehensive Income (Loss) (“AOCI”) to our condensed consolidated statements of income. Foreign currency derivatives for which we have not elected hedge accounting consist of certain forward contracts, and any changes in the fair value of these derivatives are recorded in our condensed consolidated statements of income. These undesignated derivatives are used to hedge monetary net asset and liability positions. Cash flows from our foreign currency derivatives are classified as cash flows from operating activities in our condensed consolidated statements of cash flows, which is consistent with the classification of the cash flows from the underlying hedged item. We evaluate our derivatives designated as cash flow hedges each quarter to assess hedge effectiveness. Interest Rate Risk Interest on our outstanding debt as of November 30, 2024 and February 29, 2024 is based on floating interest rates. If short-term interest rates increase, we will incur higher interest expense on any future outstanding balances of floating rate debt. Floating interest rates are hedged with interest rate swaps to effectively fix interest rates on a portion of our outstanding principal balance under the Credit Agreement, which totaled $739.2 million and $672.0 million as of November 30, 2024 and February 29, 2024, respectively. As of November 30, 2024 and February 29, 2024, $550.0 million and $500.0 million of the outstanding principal balance under the Credit Agreement, respectively, was hedged with interest rate swaps to fix the interest rate we pay. Our interest rate swaps are designated as cash flow hedges and are recorded on the balance sheet at fair value with changes in fair value recorded in OCI until the hedge transaction is settled, at which point amounts are reclassified from AOCI to our condensed consolidated statements of income. Cash flows from our interest rate swaps are classified as cash flows from operating activities in our condensed consolidated statements of cash flows, which is consistent with the classification of the cash flows from the underlying hedged item. We evaluate our derivatives designated as cash flow hedges each quarter to assess hedge effectiveness. The following tables summarize the fair values of our derivative instruments as of the end of the periods presented: (in thousands) November 30, 2024 Derivatives designated as hedging instruments Hedge Final Notional Amount Prepaid Other Assets Accrued Other Forward contracts - sell Euro Cash flow 2/2026 € 31,250 $ 1,464 $ 202 $ — $ — Forward contracts - sell Canadian Dollars Cash flow 2/2025 $ 6,150 187 — — — Forward contracts - sell Pounds Cash flow 2/2026 £ 25,825 415 163 87 — Forward contracts - sell Norwegian Kroner Cash flow 8/2025 kr 12,000 62 — — — Interest rate swaps Cash flow 8/2026 $ 550,000 1,153 585 — — Subtotal 3,281 950 87 — Derivatives not designated under hedge accounting Forward contracts - sell Euro (1) 12/2024 € 1,800 3 — — — Forward contracts - sell Pounds (1) 12/2024 £ 1,880 — — 8 — Subtotal 3 — 8 — Total fair value $ 3,284 $ 950 $ 95 $ — (in thousands) February 29, 2024 Derivatives designated as hedging instruments Hedge Type Final Notional Amount Prepaid Other Assets Accrued Other Forward contracts - sell Euro Cash flow 2/2025 € 36,500 $ 377 $ — $ 90 $ — Forward contracts - sell Canadian Dollars Cash flow 2/2025 $ 20,750 151 — 57 — Forward contracts - sell Pounds Cash flow 2/2025 £ 20,250 59 — 234 — Forward contracts - sell Norwegian Kroner Cash flow 8/2024 kr 5,000 5 — — — Interest rate swaps Cash flow 2/2026 $ 500,000 1,314 1,190 — — Subtotal 1,906 1,190 381 — Derivatives not designated under hedge accounting Forward contracts - sell Euro (1) 3/2024 € 430 — — 3 — Forward contracts - sell Pounds (1) 3/2024 £ 735 — — 2 — Subtotal — — 5 — Total fair value $ 1,906 $ 1,190 $ 386 $ — (1) These forward contracts, for which we have not elected hedge accounting, hedge monetary net asset and liability positions for the notional amounts reported, creating an economic hedge against currency movements. The pre-tax effects of derivative instruments designated as cash flow hedges were as follows for the periods presented: Three Months Ended November 30, Gain (Loss) Gain (Loss) Reclassified (in thousands) 2024 2023 Location 2024 2023 Foreign currency contracts - cash flow hedges $ 3,607 $ 278 Sales revenue, net $ (4) $ 212 Interest rate swaps - cash flow hedges 3,788 8 Interest expense 1,262 2,213 Total $ 7,395 $ 286 $ 1,258 $ 2,425 Nine Months Ended November 30, Gain (Loss) Gain (Loss) Reclassified (in thousands) 2024 2023 Location 2024 2023 Foreign currency contracts - cash flow hedges $ 2,182 $ (968) Sales revenue, net $ (13) $ 167 Interest rate swaps - cash flow hedges 2,545 3,018 Interest expense 3,311 5,647 Total $ 4,727 $ 2,050 $ 3,298 $ 5,814 The pre-tax effects of derivative instruments not designated under hedge accounting were as follows for the periods presented: Gain (Loss) Three Months Ended November 30, Nine Months Ended November 30, (in thousands) Location 2024 2023 2024 2023 Forward contracts SG&A $ (67) $ (225) $ 21 $ (265) Total $ (67) $ (225) $ 21 $ (265) We expect a net gain of $3.2 million associated with foreign currency contracts and interest rate swaps currently recorded in AOCI to be reclassified into income over the next twelve months. The amount ultimately realized, however, will differ as exchange rates and interest rates change and the underlying contracts settle. See Notes 9 and 11 for more information. Counterparty Credit Risk Financial instruments, including foreign currency contracts, forward contracts, and interest rate swaps, expose us to counterparty credit risk for non-performance. We manage our exposure to counterparty credit risk by only dealing with counterparties who are substantial international financial institutions with significant experience using such derivative instruments. We believe that the risk of incurring credit losses is remote.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Loss)	9 Months Ended
	Nov. 30, 2024
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]
Accumulated Other Comprehensive Income (Loss)	Note 11 - Accumulated Other Comprehensive Income (Loss) The changes in AOCI by component and related tax effects for the periods presented were as follows: (in thousands) Interest Foreign Total Balance at February 28, 2023 $ 4,394 $ 553 $ 4,947 Other comprehensive income (loss) before reclassification 3,018 (968) 2,050 Amounts reclassified out of AOCI (5,647) (167) (5,814) Tax effects 619 256 875 Other comprehensive loss (2,010) (879) (2,889) Balance at November 30, 2023 $ 2,384 $ (326) $ 2,058 Balance at February 29, 2024 $ 1,917 $ 182 $ 2,099 Other comprehensive income before reclassification 2,545 2,182 4,727 Amounts reclassified out of AOCI (3,311) 13 (3,298) Tax effects 179 (464) (285) Other comprehensive (loss) income (587) 1,731 1,144 Balance at November 30, 2024 $ 1,330 $ 1,913 $ 3,243 See Notes 9 and 10 for additional information regarding our cash flow hedges.

Segment and Geographic Informat

Segment and Geographic Information	9 Months Ended
	Nov. 30, 2024
Segment Reporting [Abstract]
Segment and Geographic Information	Note 12 - Segment and Geographic Information The following tables summarize segment information for the periods presented: Three Months Ended November 30, 2024 (in thousands) Home & Outdoor Beauty & Wellness Total Sales revenue, net $ 246,109 $ 284,597 $ 530,706 Restructuring charges 770 2,748 3,518 Operating income 40,313 34,805 75,118 Capital and intangible asset expenditures 2,976 5,153 8,129 Depreciation and amortization 6,336 6,886 13,222 Three Months Ended November 30, 2023 (in thousands) Home & Outdoor Beauty & Wellness Total Sales revenue, net $ 235,948 $ 313,666 $ 549,614 Restructuring charges 583 3,307 3,890 Operating income 49,514 57,413 106,927 Capital and intangible asset expenditures 7,674 1,450 9,124 Depreciation and amortization 6,025 6,406 12,431 Nine Months Ended November 30, 2024 (in thousands) Home & Outdoor Beauty & Wellness Total Sales revenue, net $ 686,512 $ 735,262 $ 1,421,774 Restructuring charges 1,728 5,151 6,879 Operating income 87,315 53,418 140,733 Capital and intangible asset expenditures 10,443 11,712 22,155 Depreciation and amortization 19,573 21,277 40,850 Nine Months Ended November 30, 2023 (in thousands) Home & Outdoor Beauty & Wellness Total Sales revenue, net $ 693,069 $ 822,780 $ 1,515,849 Restructuring charges 4,644 10,218 14,862 Operating income 107,729 86,684 194,413 Capital and intangible asset expenditures 23,513 6,168 29,681 Depreciation and amortization 17,033 20,004 37,037 The following table presents net sales revenue by geographic region, in U.S. Dollars: Three Months Ended November 30, Nine Months Ended November 30, (in thousands) 2024 2023 2024 2023 Domestic sales revenue, net (1) $ 400,539 75.5 % $ 428,582 78.0 % $ 1,066,969 75.0 % $ 1,176,190 77.6 % International sales revenue, net 130,167 24.5 % 121,032 22.0 % 354,805 25.0 % 339,659 22.4 % Total sales revenue, net $ 530,706 100.0 % $ 549,614 100.0 % $ 1,421,774 100.0 % $ 1,515,849 100.0 % (1)

Income Taxes

Income Taxes	9 Months Ended
	Nov. 30, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Note 13 - Income Taxes We reorganized the Company in Bermuda in 1994 and many of our foreign subsidiaries are not directly or indirectly owned by a U.S. parent. As such, a large portion of our foreign income is not subject to U.S. taxation on a permanent basis under current law. Additionally, our intellectual property is largely owned by foreign subsidiaries, resulting in proportionally higher earnings in jurisdictions with lower statutory tax rates, which decreases our overall effective tax rate. The taxable income earned in each jurisdiction, whether U.S. or foreign, is determined by the subsidiary's operating results and transfer pricing and tax regulations in the related jurisdictions. For interim periods, our income tax expense and resulting effective tax rate are based upon an estimated annual effective tax rate adjusted for the effects of items required to be treated as discrete to the period, including changes in tax laws, changes in estimated exposures for uncertain tax positions and other items. The Organisation for Economic Co-operation and Development has introduced a framework to implement a global minimum corporate income tax of 15%, referred to as “Pillar Two.” Certain countries have adopted legislation to implement Pillar Two, and other countries are in the process of introducing legislation to implement Pillar Two. Many aspects of Pillar Two are effective for tax years beginning after January 1, 2024, with certain remaining aspects to be effective for tax years beginning January 1, 2025 or later. Pillar Two legislation in effect for our fiscal year 2025 has been incorporated into our financial statements. We will continue to assess the impact of Pillar Two and monitor developments in legislation, regulation, and interpretive guidance. In response to Pillar Two, on May 24, 2024, Barbados enacted a domestic corporate income tax rate of 9%, effective beginning with our fiscal year 2025. As a result, we incorporated this corporate income tax into our estimated annual effective tax rate increasing our income tax provision beginning in the first quarter of fiscal 2025. In addition, we revalued our existing deferred tax liabilities subject to the Barbados legislation, which resulted in a discrete tax charge of $6.0 million during the first quarter of fiscal 2025. Additionally, Barbados enacted a domestic minimum top-up tax (“DMTT”) of 15% which applies to Barbados businesses that are part of multinational enterprise groups with annual revenue of €750 million or more and is effective beginning with our fiscal year 2026. We will continue to monitor and evaluate impacts as further regulatory guidance becomes available. For the three months ended November 30, 2024, income tax expense as a percentage of income before income tax was 21.4% compared to 19.5% for the same period last year. The year-over-year increase in the effective tax rate is primarily due to the Barbados tax legislation enacted during the first quarter of fiscal 2025, which resulted in an increase in our income tax expense due to the change to our estimated annual effective tax rate arising from the legislation, and an increase in tax expense for discrete items, partially offset by the comparative impact of tax expense recognized during the third quarter of fiscal 2024 for the gain on the sale of the El Paso facility and shifts in the mix of income in our various tax jurisdictions. For the nine months ended November 30, 2024, income tax expense as a percentage of income before income tax was 29.5% compared to 18.4% for the same period last year primarily due to the Barbados tax legislation described above, including a discrete tax charge of $6.0 million during the first quarter of fiscal 2025 to revalue deferred tax liabilities, and an increase in tax expense for discrete items, partially offset by the comparative impact of tax expense recognized during the third quarter of fiscal 2024 for the gain on the sale of the El Paso facility and shifts in the mix of income in our various tax jurisdictions.

Earnings Per Share

Earnings Per Share	9 Months Ended
	Nov. 30, 2024
Earnings Per Share [Abstract]
Earnings Per Share	Note 14 - Earnings Per Share We compute basic earnings per share using the weighted average number of shares of common stock outstanding during the period. We compute diluted earnings per share using the weighted average number of shares of common stock outstanding plus the effect of dilutive securities. Dilutive securities at any given point in time may consist of outstanding options to purchase common stock and issued and contingently issuable unvested restricted stock units, performance stock units, restricted stock awards and performance restricted stock awards and other stock-based awards. Anti-dilutive securities are not included in the computation of diluted earnings per share under the treasury stock method. See Note 4 to these condensed consolidated financial statements for more information regarding stock-based awards. The following table presents our weighted average basic and diluted shares outstanding for the periods shown: Three Months Ended November 30, Nine Months Ended November 30, (in thousands) 2024 2023 2024 2023 Weighted average shares outstanding, basic 22,853 23,743 23,064 23,903 Incremental shares from share-based compensation arrangements 29 70 54 93 Weighted average shares outstanding, diluted 22,882 23,813 23,118 23,996 Anti-dilutive securities 123 9 134 57

Subsequent Event

Subsequent Event	9 Months Ended
	Nov. 30, 2024
Subsequent Events [Abstract]
Subsequent Event	Note 15 - Subsequent Event

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Nov. 30, 2024	Nov. 30, 2023	Nov. 30, 2024	Nov. 30, 2023
Pay vs Performance Disclosure
Net income	$ 49,616	$ 75,898	$ 72,834	$ 125,860

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Nov. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Basis of Presentation and Rel_2

Basis of Presentation and Related Information (Policies)	9 Months Ended
	Nov. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Principles of Consolidation	Principles of Consolidation The accompanying condensed consolidated financial statements are prepared in accordance with GAAP and include all of our subsidiaries. Our condensed consolidated financial statements are prepared in U.S. Dollars. All intercompany balances and transactions are eliminated in consolidation. The preparation of consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. Actual results may differ materially from those estimates.
New Accounting Pronouncements, Not Yet Adopted	Not Yet Adopted In November 2024, the FASB issued ASU 2024-03, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	9 Months Ended
	Nov. 30, 2024
Payables and Accruals [Abstract]
Schedule of accrued expenses and other current liabilities	A summary of accrued expenses and other current liabilities was as follows: (in thousands) November 30, 2024 February 29, 2024 Accrued compensation, benefits and payroll taxes $ 19,125 $ 36,572 Accrued sales discounts and allowances 48,839 37,851 Accrued sales returns 22,118 21,282 Accrued advertising 34,658 29,212 Other 58,019 56,474 Total accrued expenses and other current liabilities $ 182,759 $ 181,391

Share-Based Compensation Plans

Share-Based Compensation Plans (Tables)	9 Months Ended
	Nov. 30, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of share-based compensation expense in SG&A	We recorded share-based compensation expense in SG&A as follows: Three Months Ended November 30, Nine Months Ended (in thousands) 2024 2023 2024 2023 Directors stock compensation $ 197 $ 197 $ 589 $ 590 Service Condition Awards 2,711 3,160 8,105 9,358 Performance Condition Awards 563 1,170 2,703 4,306 Market Condition Awards 842 3,458 3,609 9,647 Employee stock purchase plan 417 594 1,044 1,204 Share-based compensation expense 4,730 8,579 16,050 25,105 Less: income tax benefits (354) (532) (839) (1,558) Share-based compensation expense, net of income tax benefits $ 4,376 $ 8,047 $ 15,211 $ 23,547

Repurchases of Common Stock (Ta

Repurchases of Common Stock (Tables)	9 Months Ended
	Nov. 30, 2024
Equity [Abstract]
Schedule of share repurchase activity	The following table summarizes our share repurchase activity for the periods shown: Three Months Ended November 30, Nine Months Ended November 30, (in thousands, except share and per share data) 2024 2023 2024 2023 Common stock repurchased on the open market: Number of shares — — 1,011,243 381,200 Aggregate value of shares $ — $ — $ 100,019 $ 50,006 Average price per share $ — $ — $ 98.91 $ 131.18 Common stock received in connection with share-based compensation: Number of shares 448 2,701 27,223 48,098 Aggregate value of shares $ 30 $ 306 $ 3,155 $ 4,835 Average price per share $ 66.34 $ 113.31 $ 115.89 $ 100.51

Restructuring Plan (Tables)

Restructuring Plan (Tables)	9 Months Ended
	Nov. 30, 2024
Restructuring and Related Activities [Abstract]
Schedule of restructuring charges recorded	The following tables summarize restructuring charges recorded as a result of Project Pegasus for the periods presented: Three Months Ended November 30, 2024 (in thousands) Home & Beauty & Total Severance and employee related costs $ 130 $ 489 $ 619 Professional fees 59 355 414 Contract termination — 1,747 1,747 Other 581 157 738 Total restructuring charges $ 770 $ 2,748 $ 3,518 Three Months Ended November 30, 2023 (in thousands) Home & Beauty & Total Severance and employee related costs $ 109 $ 2,498 $ 2,607 Professional fees 464 794 1,258 Contract termination — — — Other 10 15 25 Total restructuring charges $ 583 $ 3,307 $ 3,890 Nine Months Ended November 30, 2024 Total (in thousands) Home & Beauty & Wellness Total Severance and employee related costs $ 820 $ 2,155 $ 2,975 $ 18,251 Professional fees 327 940 1,267 28,144 Contract termination — 1,747 1,747 3,078 Other 581 309 890 3,480 Total restructuring charges $ 1,728 $ 5,151 $ 6,879 $ 52,953 Nine Months Ended November 30, 2023 (in thousands) Home & Beauty & Total Severance and employee related costs $ 680 $ 3,407 $ 4,087 Professional fees 3,915 5,870 9,785 Contract termination — 796 796 Other 49 145 194 Total restructuring charges $ 4,644 $ 10,218 $ 14,862
Schedule of rollforward of restructuring reserve	The tables below present a rollforward of our accruals related to Project Pegasus, which are included in accounts payable and accrued expenses and other current liabilities: (in thousands) Balance at February 29, 2024 Charges Payments Balance at November 30, 2024 Severance and employee related costs $ 4,493 $ 2,975 $ (5,885) $ 1,583 Professional fees 272 1,267 (1,303) 236 Contract termination — 1,747 (1,735) 12 Other — 890 (890) — Total $ 4,765 $ 6,879 $ (9,813) $ 1,831 (in thousands) Balance at February 28, 2023 Charges Payments Balance at November 30, 2023 Severance and employee related costs $ 3,173 $ 4,087 $ (3,758) $ 3,502 Professional fees 3,201 9,785 (12,559) 427 Contract termination 160 796 (956) — Other 34 194 (228) — Total $ 6,568 $ 14,862 $ (17,501) $ 3,929

Long-Term Debt (Tables)

Long-Term Debt (Tables)	9 Months Ended
	Nov. 30, 2024
Debt Disclosure [Abstract]
Schedule of long-term debt	A summary of our long-term debt follows: (in thousands) November 30, 2024 February 29, 2024 Credit Agreement (1): Revolving loans $ 493,900 $ 421,950 Term loans 245,313 250,000 Total borrowings under Credit Agreement 739,213 671,950 Unamortized prepaid financing fees (5,322) (6,279) Total long-term debt 733,891 665,671 Less: current maturities of long-term debt (8,594) (6,250) Long-term debt, excluding current maturities $ 725,297 $ 659,421 (1) The weighted average interest rates on borrowings outstanding under the Credit Agreement (defined below) inclusive of the impact of our interest rate swaps as of November 30, 2024 and February 29, 2024 were 5.5% and 6.0%, respectively.

Fair Value (Tables)

Fair Value (Tables)	9 Months Ended
	Nov. 30, 2024
Fair Value Disclosures [Abstract]
Schedule of financial assets and liabilities	The following table presents the fair value of our financial assets and liabilities: Fair Value (in thousands) November 30, 2024 February 29, 2024 Assets: Cash equivalents (money market accounts) $ 8,898 $ 462 U.S. Treasury Bills 10,715 8,948 Interest rate swaps 1,738 2,504 Foreign currency derivatives 2,496 592 Total assets $ 23,847 $ 12,506 Liabilities: Interest rate swaps $ — $ — Foreign currency derivatives 95 386 Total liabilities $ 95 $ 386

Financial Instruments and Ris_2

Financial Instruments and Risk Management (Tables)	9 Months Ended
	Nov. 30, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of fair values of derivative instruments	The following tables summarize the fair values of our derivative instruments as of the end of the periods presented: (in thousands) November 30, 2024 Derivatives designated as hedging instruments Hedge Final Notional Amount Prepaid Other Assets Accrued Other Forward contracts - sell Euro Cash flow 2/2026 € 31,250 $ 1,464 $ 202 $ — $ — Forward contracts - sell Canadian Dollars Cash flow 2/2025 $ 6,150 187 — — — Forward contracts - sell Pounds Cash flow 2/2026 £ 25,825 415 163 87 — Forward contracts - sell Norwegian Kroner Cash flow 8/2025 kr 12,000 62 — — — Interest rate swaps Cash flow 8/2026 $ 550,000 1,153 585 — — Subtotal 3,281 950 87 — Derivatives not designated under hedge accounting Forward contracts - sell Euro (1) 12/2024 € 1,800 3 — — — Forward contracts - sell Pounds (1) 12/2024 £ 1,880 — — 8 — Subtotal 3 — 8 — Total fair value $ 3,284 $ 950 $ 95 $ — (in thousands) February 29, 2024 Derivatives designated as hedging instruments Hedge Type Final Notional Amount Prepaid Other Assets Accrued Other Forward contracts - sell Euro Cash flow 2/2025 € 36,500 $ 377 $ — $ 90 $ — Forward contracts - sell Canadian Dollars Cash flow 2/2025 $ 20,750 151 — 57 — Forward contracts - sell Pounds Cash flow 2/2025 £ 20,250 59 — 234 — Forward contracts - sell Norwegian Kroner Cash flow 8/2024 kr 5,000 5 — — — Interest rate swaps Cash flow 2/2026 $ 500,000 1,314 1,190 — — Subtotal 1,906 1,190 381 — Derivatives not designated under hedge accounting Forward contracts - sell Euro (1) 3/2024 € 430 — — 3 — Forward contracts - sell Pounds (1) 3/2024 £ 735 — — 2 — Subtotal — — 5 — Total fair value $ 1,906 $ 1,190 $ 386 $ — (1)
Schedule of pre-tax effect of derivative instruments designated as hedges	The pre-tax effects of derivative instruments designated as cash flow hedges were as follows for the periods presented: Three Months Ended November 30, Gain (Loss) Gain (Loss) Reclassified (in thousands) 2024 2023 Location 2024 2023 Foreign currency contracts - cash flow hedges $ 3,607 $ 278 Sales revenue, net $ (4) $ 212 Interest rate swaps - cash flow hedges 3,788 8 Interest expense 1,262 2,213 Total $ 7,395 $ 286 $ 1,258 $ 2,425 Nine Months Ended November 30, Gain (Loss) Gain (Loss) Reclassified (in thousands) 2024 2023 Location 2024 2023 Foreign currency contracts - cash flow hedges $ 2,182 $ (968) Sales revenue, net $ (13) $ 167 Interest rate swaps - cash flow hedges 2,545 3,018 Interest expense 3,311 5,647 Total $ 4,727 $ 2,050 $ 3,298 $ 5,814
Schedule of pre-tax effect of derivative instruments not designated as hedges	The pre-tax effects of derivative instruments not designated under hedge accounting were as follows for the periods presented: Gain (Loss) Three Months Ended November 30, Nine Months Ended November 30, (in thousands) Location 2024 2023 2024 2023 Forward contracts SG&A $ (67) $ (225) $ 21 $ (265) Total $ (67) $ (225) $ 21 $ (265)

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Loss) (Tables)	9 Months Ended
	Nov. 30, 2024
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]
Schedule of changes in accumulated other comprehensive income (loss)	The changes in AOCI by component and related tax effects for the periods presented were as follows: (in thousands) Interest Foreign Total Balance at February 28, 2023 $ 4,394 $ 553 $ 4,947 Other comprehensive income (loss) before reclassification 3,018 (968) 2,050 Amounts reclassified out of AOCI (5,647) (167) (5,814) Tax effects 619 256 875 Other comprehensive loss (2,010) (879) (2,889) Balance at November 30, 2023 $ 2,384 $ (326) $ 2,058 Balance at February 29, 2024 $ 1,917 $ 182 $ 2,099 Other comprehensive income before reclassification 2,545 2,182 4,727 Amounts reclassified out of AOCI (3,311) 13 (3,298) Tax effects 179 (464) (285) Other comprehensive (loss) income (587) 1,731 1,144 Balance at November 30, 2024 $ 1,330 $ 1,913 $ 3,243

Segment and Geographic Inform_2

Segment and Geographic Information (Tables)	9 Months Ended
	Nov. 30, 2024
Segment Reporting [Abstract]
Schedule of segment information	The following tables summarize segment information for the periods presented: Three Months Ended November 30, 2024 (in thousands) Home & Outdoor Beauty & Wellness Total Sales revenue, net $ 246,109 $ 284,597 $ 530,706 Restructuring charges 770 2,748 3,518 Operating income 40,313 34,805 75,118 Capital and intangible asset expenditures 2,976 5,153 8,129 Depreciation and amortization 6,336 6,886 13,222 Three Months Ended November 30, 2023 (in thousands) Home & Outdoor Beauty & Wellness Total Sales revenue, net $ 235,948 $ 313,666 $ 549,614 Restructuring charges 583 3,307 3,890 Operating income 49,514 57,413 106,927 Capital and intangible asset expenditures 7,674 1,450 9,124 Depreciation and amortization 6,025 6,406 12,431 Nine Months Ended November 30, 2024 (in thousands) Home & Outdoor Beauty & Wellness Total Sales revenue, net $ 686,512 $ 735,262 $ 1,421,774 Restructuring charges 1,728 5,151 6,879 Operating income 87,315 53,418 140,733 Capital and intangible asset expenditures 10,443 11,712 22,155 Depreciation and amortization 19,573 21,277 40,850 Nine Months Ended November 30, 2023 (in thousands) Home & Outdoor Beauty & Wellness Total Sales revenue, net $ 693,069 $ 822,780 $ 1,515,849 Restructuring charges 4,644 10,218 14,862 Operating income 107,729 86,684 194,413 Capital and intangible asset expenditures 23,513 6,168 29,681 Depreciation and amortization 17,033 20,004 37,037 The following table presents net sales revenue by geographic region, in U.S. Dollars: Three Months Ended November 30, Nine Months Ended November 30, (in thousands) 2024 2023 2024 2023 Domestic sales revenue, net (1) $ 400,539 75.5 % $ 428,582 78.0 % $ 1,066,969 75.0 % $ 1,176,190 77.6 % International sales revenue, net 130,167 24.5 % 121,032 22.0 % 354,805 25.0 % 339,659 22.4 % Total sales revenue, net $ 530,706 100.0 % $ 549,614 100.0 % $ 1,421,774 100.0 % $ 1,515,849 100.0 % (1)

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Nov. 30, 2024
Earnings Per Share [Abstract]
Schedule of components of basic and diluted shares	The following table presents our weighted average basic and diluted shares outstanding for the periods shown: Three Months Ended November 30, Nine Months Ended November 30, (in thousands) 2024 2023 2024 2023 Weighted average shares outstanding, basic 22,853 23,743 23,064 23,903 Incremental shares from share-based compensation arrangements 29 70 54 93 Weighted average shares outstanding, diluted 22,882 23,813 23,118 23,996 Anti-dilutive securities 123 9 134 57

Basis of Presentation and Rel_3

Basis of Presentation and Related Information (Details)		3 Months Ended			9 Months Ended
	Sep. 28, 2023 USD ($)	Nov. 30, 2024 USD ($) $ / shares	Aug. 31, 2024 USD ($)	Nov. 30, 2023 USD ($)	Nov. 30, 2024 segment $ / shares	Feb. 29, 2024 $ / shares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common shares, par value (in dollars per share) | $ / shares		$ 0.10			$ 0.10	$ 0.10
Number of segments | segment					2
Goodwill and intangible asset impairment		$ 0	$ 0
Distribution and Office Facilities, El Paso, Texas
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Purchase price from sale	$ 50,600,000
Transaction costs	$ 1,100,000
Term of lease	18 months
Fair value of prepaid rent	$ 1,900,000
Increase in purchase price				$ 1,900,000
Accumulated depreciation on asset held-for-sale	36,800,000
Distribution and Office Facilities, El Paso, Texas | Disposal Group, Held-for-Sale, Not Discontinued Operations
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Expected gain on sale				34,200,000
Property and equipment transferred to assets held-for-sale	$ 17,200,000
Distribution and Office Facilities, El Paso, Texas | Disposal Group, Held-for-Sale, Not Discontinued Operations | Beauty & Wellness
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Expected gain on sale				18,000,000
Distribution and Office Facilities, El Paso, Texas | Disposal Group, Held-for-Sale, Not Discontinued Operations | Home & Outdoor
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Expected gain on sale				$ 16,200,000

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Nov. 30, 2024	Feb. 29, 2024
Payables and Accruals [Abstract]
Accrued compensation, benefits and payroll taxes	$ 19,125	$ 36,572
Accrued sales discounts and allowances	48,839	37,851
Accrued sales returns	22,118	21,282
Accrued advertising	34,658	29,212
Other	58,019	56,474
Total accrued expenses and other current liabilities	$ 182,759	$ 181,391

Share-Based Compensation Plan_2

Share-Based Compensation Plans - Narrative (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended	9 Months Ended
	May 31, 2024	Nov. 30, 2024	Feb. 28, 2023
Share-based compensation plans
Unrecognized share-based compensation		$ 22.5
Expected recognition period for unrecognized share-based compensation		2 years 1 month 6 days
Target achievement for performance condition awards, as a percentage			0%
Service Condition Awards
Share-based compensation plans
Number of awards granted (in shares)	94,900
Grant date fair value of shares granted in period (in dollars per share)	$ 124.37
Performance Shares
Share-based compensation plans
Number of awards granted (in shares)	157,797
Performance Condition Awards
Share-based compensation plans
Number of awards granted (in shares)	94,586
Grant date fair value of shares granted in period (in dollars per share)	$ 124.37
Market Condition Awards
Share-based compensation plans
Number of awards granted (in shares)	63,211
Grant date fair value of shares granted in period (in dollars per share)	$ 91.19

Share-Based Compensation Plan_3

Share-Based Compensation Plans - Schedule of Share-based Compensation Expense in SG&A (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Nov. 30, 2024	Nov. 30, 2023	Nov. 30, 2024	Nov. 30, 2023
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense, net of income tax benefits	$ 4,376	$ 8,047	$ 15,211	$ 23,547
SG&A
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	4,730	8,579	16,050	25,105
Less: income tax benefits	(354)	(532)	(839)	(1,558)
Service Condition Awards | SG&A
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	2,711	3,160	8,105	9,358
Performance Condition Awards | SG&A
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	563	1,170	2,703	4,306
Market Condition Awards | SG&A
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	842	3,458	3,609	9,647
Employee stock purchase plan | SG&A
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	417	594	1,044	1,204
Directors stock compensation | SG&A
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	$ 197	$ 197	$ 589	$ 590

Repurchases of Common Stock - N

Repurchases of Common Stock - Narrative (Details) - USD ($)	Aug. 20, 2024	Nov. 30, 2024	Aug. 19, 2024
Equity [Abstract]
Amount of shares authorized for purchase	$ 500,000,000
Period for stock repurchase	3 years
Remaining share repurchase amount		$ 499,900,000	$ 245,300,000

Repurchases of Common Stock - S

Repurchases of Common Stock - Schedule of Share Repurchase Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Nov. 30, 2024	Aug. 31, 2024	May 31, 2024	Nov. 30, 2023	Aug. 31, 2023	May 31, 2023	Nov. 30, 2024	Nov. 30, 2023
Repurchase of common stock
Aggregate value of shares	$ 30	$ 109	$ 103,035	$ 306	$ 50,089	$ 4,446
Stock Compensation Plan
Repurchase of common stock
Number of shares (in shares)	448			2,701			27,223	48,098
Aggregate value of shares	$ 30			$ 306			$ 3,155	$ 4,835
Average price per share (in dollars per share)	$ 66.34			$ 113.31			$ 115.89	$ 100.51
Open Market
Repurchase of common stock
Number of shares (in shares)	0			0			1,011,243	381,200
Aggregate value of shares	$ 0			$ 0			$ 100,019	$ 50,006
Average price per share (in dollars per share)	$ 0			$ 0			$ 98.91	$ 131.18

Restructuring Plan - Narrative

Restructuring Plan - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		30 Months Ended
	Nov. 30, 2024	Nov. 30, 2023	Nov. 30, 2024	Nov. 30, 2023	Nov. 30, 2024	Feb. 28, 2023
Restructuring Plan
Restructuring charges	$ 3,518	$ 3,890	$ 6,879	$ 14,862
Project Pegasus
Restructuring Plan
Estimated percentage of workforce reduction						10%
Estimated percentage reduction in cost of goods sold	60%
Estimated percentage reduction in SG&A expenses	40%
Restructuring charges	$ 3,518	3,890	6,879	14,862	$ 52,953
Project Pegasus | Home & Outdoor
Restructuring Plan
Restructuring charges	770	583	1,728	4,644
Project Pegasus | Beauty & Wellness
Restructuring Plan
Restructuring charges	2,748	$ 3,307	5,151	10,218
Project Pegasus | Severance and employee related costs
Restructuring Plan
Restructuring charges			2,975	4,087
Project Pegasus | Professional fees
Restructuring Plan
Expected restructuring costs	28,000		28,000		28,000
Restructuring charges			1,267	9,785
Project Pegasus | Contract termination
Restructuring Plan
Restructuring charges			1,747	796
Project Pegasus | Other
Restructuring Plan
Restructuring charges			$ 890	$ 194
Project Pegasus | Fiscal 2024
Restructuring Plan
Estimated percentage of savings recognized			25%
Project Pegasus | Fiscal 2025
Restructuring Plan
Estimated percentage of savings recognized			35%
Project Pegasus | Fiscal 2026
Restructuring Plan
Estimated percentage of savings recognized			25%
Project Pegasus | Fiscal 2027
Restructuring Plan
Estimated percentage of savings recognized			15%
Project Pegasus | Minimum
Restructuring Plan
Expected restructuring costs	50,000		$ 50,000		50,000
Annualized profit improvements	75,000
Project Pegasus | Minimum | Home & Outdoor
Restructuring Plan
Expected restructuring costs	16,000		16,000		16,000
Project Pegasus | Minimum | Beauty & Wellness
Restructuring Plan
Expected restructuring costs	34,000		34,000		34,000
Project Pegasus | Minimum | Severance and employee related costs
Restructuring Plan
Expected restructuring costs	15,000		15,000		15,000
Project Pegasus | Minimum | Contract termination
Restructuring Plan
Expected restructuring costs	3,000		3,000		3,000
Project Pegasus | Maximum
Restructuring Plan
Expected restructuring costs	55,000		55,000		55,000
Annualized profit improvements	85,000
Project Pegasus | Maximum | Home & Outdoor
Restructuring Plan
Expected restructuring costs	17,000		17,000		17,000
Project Pegasus | Maximum | Beauty & Wellness
Restructuring Plan
Expected restructuring costs	38,000		38,000		38,000
Project Pegasus | Maximum | Severance and employee related costs
Restructuring Plan
Expected restructuring costs	19,000		19,000		19,000
Project Pegasus | Maximum | Contract termination
Restructuring Plan
Expected restructuring costs	4,000		4,000		4,000
Project Pegasus | Maximum | Other
Restructuring Plan
Expected restructuring costs	$ 4,000		$ 4,000		$ 4,000

Restructuring Plan - Schedule o

Restructuring Plan - Schedule of Restructuring Charges to Date (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		30 Months Ended
	Nov. 30, 2024	Nov. 30, 2023	Nov. 30, 2024	Nov. 30, 2023	Nov. 30, 2024
Restructuring Plan
Total restructuring charges	$ 3,518	$ 3,890	$ 6,879	$ 14,862
Project Pegasus
Restructuring Plan
Severance and employee related costs	619	2,607	2,975	4,087	$ 18,251
Professional fees	414	1,258	1,267	9,785	28,144
Contract termination	1,747	0	1,747	796	3,078
Other	738	25	890	194	3,480
Total restructuring charges	3,518	3,890	6,879	14,862	$ 52,953
Home & Outdoor | Project Pegasus
Restructuring Plan
Severance and employee related costs	130	109	820	680
Professional fees	59	464	327	3,915
Contract termination	0	0	0	0
Other	581	10	581	49
Total restructuring charges	770	583	1,728	4,644
Beauty & Wellness | Project Pegasus
Restructuring Plan
Severance and employee related costs	489	2,498	2,155	3,407
Professional fees	355	794	940	5,870
Contract termination	1,747	0	1,747	796
Other	157	15	309	145
Total restructuring charges	$ 2,748	$ 3,307	$ 5,151	$ 10,218

Restructuring Plan - Schedule_2

Restructuring Plan - Schedule of Reserve Roll Forward (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		30 Months Ended
	Nov. 30, 2024	Nov. 30, 2023	Nov. 30, 2024	Nov. 30, 2023	Nov. 30, 2024
Restructuring Reserve [Roll Forward]
Charges	$ 3,518	$ 3,890	$ 6,879	$ 14,862
Project Pegasus
Restructuring Reserve [Roll Forward]
Restructuring liability, beginning balance			4,765	6,568
Charges	3,518	3,890	6,879	14,862	$ 52,953
Payments			(9,813)	(17,501)
Restructuring liability, ending balance	1,831	3,929	1,831	3,929	1,831
Severance and employee related costs | Project Pegasus
Restructuring Reserve [Roll Forward]
Restructuring liability, beginning balance			4,493	3,173
Charges			2,975	4,087
Payments			(5,885)	(3,758)
Restructuring liability, ending balance	1,583	3,502	1,583	3,502	1,583
Professional fees | Project Pegasus
Restructuring Reserve [Roll Forward]
Restructuring liability, beginning balance			272	3,201
Charges			1,267	9,785
Payments			(1,303)	(12,559)
Restructuring liability, ending balance	236	427	236	427	236
Contract termination | Project Pegasus
Restructuring Reserve [Roll Forward]
Restructuring liability, beginning balance			0	160
Charges			1,747	796
Payments			(1,735)	(956)
Restructuring liability, ending balance	12	0	12	0	12
Other | Project Pegasus
Restructuring Reserve [Roll Forward]
Restructuring liability, beginning balance			0	34
Charges			890	194
Payments			(890)	(228)
Restructuring liability, ending balance	$ 0	$ 0	$ 0	$ 0	$ 0

Commitments and Contingencies (

Commitments and Contingencies (Details)	Dec. 23, 2021 renewal
Commitments and Contingencies Disclosure [Abstract]
Number of other companies named in litigation	5

Long-Term Debt - Schedule of Lo

Long-Term Debt - Schedule of Long-term Debt (Details) - USD ($) $ in Thousands	Nov. 30, 2024	Feb. 29, 2024
Long-term debt
Unamortized prepaid financing fees	$ (5,322)	$ (6,279)
Total long-term debt	733,891	665,671
Less: current maturities of long-term debt	(8,594)	(6,250)
Long-term debt, excluding current maturities	$ 725,297	$ 659,421
Line of credit
Long-term debt
Weighted average effective interest rate	5.50%	6%
Line of credit | Credit Agreement
Long-term debt
Total borrowings under Credit Agreement	$ 739,213	$ 671,950
Line of credit | Credit Agreement | Revolving loans
Long-term debt
Total borrowings under Credit Agreement	493,900	421,950
Line of credit | Credit Agreement | Term loans
Long-term debt
Total borrowings under Credit Agreement	$ 245,313	$ 250,000

Long-Term Debt - Narrative (Det

Long-Term Debt - Narrative (Details) $ in Millions		3 Months Ended		9 Months Ended
	Feb. 15, 2024 USD ($)	Nov. 30, 2024 USD ($)	Nov. 30, 2023 USD ($)	Nov. 30, 2024 USD ($)	Nov. 30, 2023 USD ($)	Feb. 29, 2024 USD ($)
Debt Instrument [Line Items]
Interest costs incurred		$ 12.2	$ 12.9	$ 37.9	$ 41.5
Interest costs capitalized		0	$ 0	0	$ 0.9
Maximum net leverage ratio	3.25
Term loans
Debt Instrument [Line Items]
Aggregate principal amount	$ 250
Revolving loans | Credit Agreement
Debt Instrument [Line Items]
Maximum revolving commitment	1,500
Line of credit
Debt Instrument [Line Items]
Fixed rate debt		550		550		$ 500
Maximum additional debt allowed under debt covenants		298.8		298.8
Maximum additional debt allowed in the event a qualified acquisition is consummated		496.6		496.6
Line of credit | Credit Agreement
Debt Instrument [Line Items]
Maximum allowable increase due to accordion feature	$ 300
Line of credit | Credit Agreement | Minimum | Base rate | Variable Rate Component One
Debt Instrument [Line Items]
Margin (as a percent)	0%
Line of credit | Credit Agreement | Minimum | SOFR | Variable Rate Component Two
Debt Instrument [Line Items]
Margin (as a percent)	1%
Line of credit | Credit Agreement | Maximum | Base rate | Variable Rate Component One
Debt Instrument [Line Items]
Margin (as a percent)	1.125%
Line of credit | Credit Agreement | Maximum | SOFR | Variable Rate Component Two
Debt Instrument [Line Items]
Margin (as a percent)	2.125%
Line of credit | Revolving loans | Credit Agreement
Debt Instrument [Line Items]
Maximum revolving commitment	$ 1,000
Proceeds from revolving credit facility	457.5
Fixed rate debt		550		550		$ 500
Amount available for borrowings		496.6		496.6
Line of credit | Letter of credit
Debt Instrument [Line Items]
Amount outstanding, letters of credit		$ 9.5		$ 9.5
Line of credit | Letter of credit | Credit Agreement
Debt Instrument [Line Items]
Maximum revolving commitment	50
Line of credit | Term loans | Credit Agreement
Debt Instrument [Line Items]
Proceeds from term loan facility	$ 250
Line of credit | Term loans | Credit Agreement | Through February 28, 2025
Debt Instrument [Line Items]
Percent of term loans due quarterly	0.625%
Line of credit | Term loans | Credit Agreement | Through February 28, 2026
Debt Instrument [Line Items]
Percent of term loans due quarterly	0.9375%
Line of credit | Term loans | Credit Agreement | After February 28th, 2026
Debt Instrument [Line Items]
Percent of term loans due quarterly	1.25%
Line of credit | Delayed Draw Term Loan (DDTL) | Credit Agreement
Debt Instrument [Line Items]
Aggregate principal amount	$ 250

Fair Value - Schedule of Financ

Fair Value - Schedule of Financial Assets and Liabilities (Details) - Recurring - Fair Values - Fair Value, Inputs, Level 2 - USD ($) $ in Thousands	Nov. 30, 2024	Feb. 29, 2024
Assets:
Cash equivalents (money market accounts)	$ 8,898	$ 462
Total assets	23,847	12,506
Liabilities:
Total liabilities	95	386
U.S. Treasury Bills
Assets:
U.S. Treasury Bills	10,715	8,948
Interest rate swaps
Assets:
Derivative assets	1,738	2,504
Liabilities:
Derivative liabilities	0	0
Foreign currency derivatives
Assets:
Derivative assets	2,496	592
Liabilities:
Derivative liabilities	$ 95	$ 386

Fair Value - Narrative (Details

Fair Value - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Nov. 30, 2024	Nov. 30, 2023	Nov. 30, 2024	Nov. 30, 2023	Feb. 29, 2024
Fair Value
Investment income, interest	$ 0.1	$ 0.1	$ 0.2	$ 0.1
U.S. Treasury Bills
Fair Value
Gross unrealized gains (losses) on US Treasury bills			$ 0		$ 0
U.S. Treasury Bills | Minimum
Fair Value
Term of US treasury bills held to maturity (less than one to five years)	1 year		1 year
U.S. Treasury Bills | Maximum
Fair Value
Term of US treasury bills held to maturity (less than one to five years)	5 years		5 years
U.S. Treasury Bills | Prepaid Expenses and Other Current Assets
Fair Value
US treasury bills, carrying value, current	$ 2.5		$ 2.5		2.5
U.S. Treasury Bills | Other Assets
Fair Value
US treasury bills, carrying value, current	2.5		2.5		2.5
US treasury bills, carrying value, non-current	$ 8.2		$ 8.2		$ 6.6

Financial Instruments and Ris_3

Financial Instruments and Risk Management - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Nov. 30, 2024	Nov. 30, 2023	Nov. 30, 2024	Nov. 30, 2023	Feb. 29, 2024
Foreign currency derivatives | Cash flow hedges
Foreign Currency Risk and Currency Exchange Uncertainties
Derivative instruments gain			$ 3,200
Period of reclassification to AOCI			12 months
Credit agreement
Foreign Currency Risk and Currency Exchange Uncertainties
Fixed rate debt	$ 550,000		$ 550,000		$ 500,000
Credit agreement | Credit Agreement
Foreign Currency Risk and Currency Exchange Uncertainties
Aggregate principal balance	739,213		739,213		$ 671,950
Income Tax Expense
Foreign Currency Risk and Currency Exchange Uncertainties
Net foreign exchange (losses) gains, including the impact of currency hedges and currency swaps	(500)	$ 100	(800)	$ 500
SG&A
Foreign Currency Risk and Currency Exchange Uncertainties
Net foreign exchange (losses) gains, including the impact of currency hedges and currency swaps	$ (1,400)	$ 100	$ (800)	$ (300)
Net sales revenue | Geographic concentration | International operations - transactions denominated in foreign currencies
Foreign Currency Risk and Currency Exchange Uncertainties
Concentration risk percentage	14%	14%	14%	14%

Financial Instruments and Ris_4

Financial Instruments and Risk Management - Schedule of Derivative FV (Details) € in Thousands, £ in Thousands, kr in Thousands, $ in Thousands, $ in Thousands	Nov. 30, 2024 EUR (€)	Nov. 30, 2024 USD ($)	Nov. 30, 2024 CAD ($)	Nov. 30, 2024 GBP (£)	Nov. 30, 2024 NOK (kr)	Feb. 29, 2024 EUR (€)	Feb. 29, 2024 USD ($)	Feb. 29, 2024 CAD ($)	Feb. 29, 2024 GBP (£)	Feb. 29, 2024 NOK (kr)
Prepaid Expenses and Other Current Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		$ 3,284					$ 1,906
Other Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		950					1,190
Accrued Expenses and Other Current Liabilities
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		95					386
Other Liabilities, Non- Current
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		0					0
Derivatives designated as hedging instruments | Prepaid Expenses and Other Current Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		3,281					1,906
Derivatives designated as hedging instruments | Other Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		950					1,190
Derivatives designated as hedging instruments | Accrued Expenses and Other Current Liabilities
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		87					381
Derivatives designated as hedging instruments | Other Liabilities, Non- Current
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		0					0
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell
Fair values of derivative instruments in the consolidated balance sheet
Notional Amount	€ 31,250		$ 6,150	£ 25,825	kr 12,000	€ 36,500		$ 20,750	£ 20,250	kr 5,000
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Euros | Prepaid Expenses and Other Current Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		1,464					377
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Euros | Other Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		202					0
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Euros | Accrued Expenses and Other Current Liabilities
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		0					90
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Euros | Other Liabilities, Non- Current
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		0					0
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Canadian Dollars | Prepaid Expenses and Other Current Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		187					151
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Canadian Dollars | Other Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		0					0
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Canadian Dollars | Accrued Expenses and Other Current Liabilities
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		0					57
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Canadian Dollars | Other Liabilities, Non- Current
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		0					0
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Pounds | Prepaid Expenses and Other Current Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		415					59
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Pounds | Other Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		163					0
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Pounds | Accrued Expenses and Other Current Liabilities
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		87					234
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Pounds | Other Liabilities, Non- Current
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		0					0
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Norwegian Kroner | Prepaid Expenses and Other Current Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		62					5
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Norwegian Kroner | Other Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		0					0
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Norwegian Kroner | Accrued Expenses and Other Current Liabilities
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		0					0
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Norwegian Kroner | Other Liabilities, Non- Current
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		0					0
Derivatives designated as hedging instruments | Interest rate swaps
Fair values of derivative instruments in the consolidated balance sheet
Notional Amount		550,000					500,000
Derivatives designated as hedging instruments | Interest rate swaps | Prepaid Expenses and Other Current Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		1,153					1,314
Derivatives designated as hedging instruments | Interest rate swaps | Other Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		585					1,190
Derivatives designated as hedging instruments | Interest rate swaps | Accrued Expenses and Other Current Liabilities
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		0					0
Derivatives designated as hedging instruments | Interest rate swaps | Other Liabilities, Non- Current
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		0					0
Derivatives not designated under hedge accounting | Prepaid Expenses and Other Current Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		3					0
Derivatives not designated under hedge accounting | Other Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		0					0
Derivatives not designated under hedge accounting | Accrued Expenses and Other Current Liabilities
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		8					5
Derivatives not designated under hedge accounting | Other Liabilities, Non- Current
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		0					0
Derivatives not designated under hedge accounting | Foreign currency derivatives | Euros | Prepaid Expenses and Other Current Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		3					0
Derivatives not designated under hedge accounting | Foreign currency derivatives | Euros | Other Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		0					0
Derivatives not designated under hedge accounting | Foreign currency derivatives | Euros | Accrued Expenses and Other Current Liabilities
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		0					3
Derivatives not designated under hedge accounting | Foreign currency derivatives | Euros | Other Liabilities, Non- Current
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		0					0
Derivatives not designated under hedge accounting | Foreign currency derivatives | Pounds | Prepaid Expenses and Other Current Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		0					0
Derivatives not designated under hedge accounting | Foreign currency derivatives | Pounds | Other Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		0					0
Derivatives not designated under hedge accounting | Foreign currency derivatives | Pounds | Accrued Expenses and Other Current Liabilities
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		8					2
Derivatives not designated under hedge accounting | Foreign currency derivatives | Pounds | Other Liabilities, Non- Current
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		$ 0					$ 0
Derivatives not designated under hedge accounting | Cross currency debt swaps
Fair values of derivative instruments in the consolidated balance sheet
Notional Amount	€ 1,800			£ 1,880		€ 430			£ 735

Financial Instruments and Ris_5

Financial Instruments and Risk Management - Schedule of Derivative Tax Effect (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Nov. 30, 2024	Nov. 30, 2023	Nov. 30, 2024	Nov. 30, 2023
Pre-tax effect of derivative instruments
Gain (Loss) Recognized in AOCI	$ 7,395	$ 286	$ 4,727	$ 2,050
Gain (Loss) Reclassified from AOCI into Income	1,258	2,425	3,298	5,814
Gain (Loss)  Recognized in Income	(67)	(225)	21	(265)
Foreign currency derivatives | Cash flow hedges
Pre-tax effect of derivative instruments
Gain (Loss) Recognized in AOCI	3,607	278	2,182	(968)
Foreign currency derivatives | Cash flow hedges | SG&A
Pre-tax effect of derivative instruments
Gain (Loss) Reclassified from AOCI into Income	(4)	212	(13)	167
Interest rate swaps | Cash flow hedges
Pre-tax effect of derivative instruments
Gain (Loss) Recognized in AOCI	3,788	8	2,545	3,018
Interest rate swaps | Cash flow hedges | Interest expense
Pre-tax effect of derivative instruments
Gain (Loss) Reclassified from AOCI into Income	1,262	2,213	3,311	5,647
Forward contracts | SG&A
Pre-tax effect of derivative instruments
Gain (Loss)  Recognized in Income	$ (67)	$ (225)	$ 21	$ (265)

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Nov. 30, 2024	Aug. 31, 2024	May 31, 2024	Nov. 30, 2023	Aug. 31, 2023	May 31, 2023	Nov. 30, 2024	Nov. 30, 2023
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	$ 1,567,580	$ 1,549,500	$ 1,637,442	$ 1,501,883	$ 1,514,908	$ 1,488,811	$ 1,637,442	$ 1,488,811
Other comprehensive income (loss) before reclassification							4,727	2,050
Amounts reclassified out of AOCI							(3,298)	(5,814)
Tax effects							(285)	875
Total other comprehensive income (loss), net of tax	4,758	(4,312)	698	(1,628)	2,454	(3,715)	1,144	(2,889)
Ending balance	1,628,176	1,567,580	1,549,500	1,586,278	1,501,883	1,514,908	1,628,176	1,586,278
Interest Rate Swaps
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance			1,917			4,394	1,917	4,394
Other comprehensive income (loss) before reclassification							2,545	3,018
Amounts reclassified out of AOCI							(3,311)	(5,647)
Tax effects							179	619
Total other comprehensive income (loss), net of tax							(587)	(2,010)
Ending balance	1,330			2,384			1,330	2,384
Foreign Currency Contracts
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance			182			553	182	553
Other comprehensive income (loss) before reclassification							2,182	(968)
Amounts reclassified out of AOCI							13	(167)
Tax effects							(464)	256
Total other comprehensive income (loss), net of tax							1,731	(879)
Ending balance	1,913			(326)			1,913	(326)
Total
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	(1,515)	2,797	2,099	3,686	1,232	4,947	2,099	4,947
Total other comprehensive income (loss), net of tax	4,758	(4,312)	698	(1,628)	2,454	(3,715)
Ending balance	$ 3,243	$ (1,515)	$ 2,797	$ 2,058	$ 3,686	$ 1,232	$ 3,243	$ 2,058

Segment and Geographic Inform_3

Segment and Geographic Information - Schedule of Segment Information by Segment (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Nov. 30, 2024	Nov. 30, 2023	Nov. 30, 2024	Nov. 30, 2023
Segment information
Sales revenue, net	$ 530,706	$ 549,614	$ 1,421,774	$ 1,515,849
Restructuring charges	3,518	3,890	6,879	14,862
Operating income	75,118	106,927	140,733	194,413
Capital and intangible asset expenditures			22,155	29,681
Depreciation and amortization			40,850	37,037
Operating Segments
Segment information
Sales revenue, net	530,706	549,614	1,421,774	1,515,849
Restructuring charges	3,518	3,890	6,879	14,862
Operating income	75,118	106,927	140,733	194,413
Capital and intangible asset expenditures	8,129	9,124	22,155	29,681
Depreciation and amortization	13,222	12,431	40,850	37,037
Home & Outdoor | Operating Segments
Segment information
Sales revenue, net	246,109	235,948	686,512	693,069
Restructuring charges	770	583	1,728	4,644
Operating income	40,313	49,514	87,315	107,729
Capital and intangible asset expenditures	2,976	7,674	10,443	23,513
Depreciation and amortization	6,336	6,025	19,573	17,033
Beauty & Wellness | Operating Segments
Segment information
Sales revenue, net	284,597	313,666	735,262	822,780
Restructuring charges	2,748	3,307	5,151	10,218
Operating income	34,805	57,413	53,418	86,684
Capital and intangible asset expenditures	5,153	1,450	11,712	6,168
Depreciation and amortization	$ 6,886	$ 6,406	$ 21,277	$ 20,004

Segment and Geographic Inform_4

Segment and Geographic Information - Schedule of Revenue by Domestic and International (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Nov. 30, 2024	Nov. 30, 2023	Nov. 30, 2024	Nov. 30, 2023
Segment information
Sales revenue, net	$ 530,706	$ 549,614	$ 1,421,774	$ 1,515,849
Domestic sales revenue, net
Segment information
Sales revenue, net	400,539	428,582	1,066,969	1,176,190
International sales revenue, net
Segment information
Sales revenue, net	$ 130,167	$ 121,032	$ 354,805	$ 339,659
Revenue from Contract with Customer Benchmark | Geographic concentration
Segment information
Concentration risk percentage	100%	100%	100%	100%
Revenue from Contract with Customer Benchmark | Geographic concentration | Domestic sales revenue, net
Segment information
Concentration risk percentage	75.50%	78%	75%	77.60%
Revenue from Contract with Customer Benchmark | Geographic concentration | International sales revenue, net
Segment information
Concentration risk percentage	24.50%	22%	25%	22.40%

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended			9 Months Ended
	Nov. 30, 2024	May 31, 2024	Nov. 30, 2023	Nov. 30, 2024	Nov. 30, 2023
Effective Income Tax Rate Reconciliation [Line Items]
Income tax expense (benefit) as a percent of income before income taxes	21.40%		19.50%	29.50%	18.40%
Foreign Tax Authority | Barbados Revenue Authority
Effective Income Tax Rate Reconciliation [Line Items]
Discrete tax charge due to change in legislation		$ 6

Earnings per Share (Details)

Earnings per Share (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Nov. 30, 2024	Nov. 30, 2023	Nov. 30, 2024	Nov. 30, 2023
Weighted average diluted securities
Weighted average shares outstanding, basic (in shares)	22,853	23,743	23,064	23,903
Incremental shares from share-based payment arrangements (in shares)	29	70	54	93
Weighted average shares outstanding, diluted (in shares)	22,882	23,813	23,118	23,996
Anti-dilutive securities
Weighted average diluted securities
Antidilutive securities (in shares)	123	9	134	57

Subsequent Event (Details)

Subsequent Event (Details) - USD ($) $ in Thousands		9 Months Ended
	Dec. 16, 2024	Nov. 30, 2024	Nov. 30, 2023
Subsequent Event [Line Items]
Proceeds from revolving loans		$ 747,840	$ 635,800
Subsequent Event | Letter of credit | Credit agreement
Subsequent Event [Line Items]
Amount available for borrowings	$ 253,600
Subsequent Event | Olive and June, LLC
Subsequent Event [Line Items]
Net payments to acquire businesses, net of cash acquired	229,400
Additional contingent consideration	15,000
Subsequent Event | Olive and June, LLC | Letter of credit | Credit agreement
Subsequent Event [Line Items]
Proceeds from revolving loans	$ 235,000